Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Care Reform For Pfizer Equals $800 Million Revenue Hit In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer maintained its 2012 earnings per share guidance, despite the lower revenue projections, however.

You may also be interested in...

ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market

FDA approves Pfizer's Prevnar 13 vaccine and ACIP's recommendations set the stage for a broadened indication and a blockbuster product.

Pfizer Lowers Targeted Revenues for 2012; Wall Street Remains Skeptical

Pfizer's touts growth plans in emerging markets as the pharma prepares for the onset of Lipitor generics.

Pfizer, Wyeth Post Lackluster Sales as They Prepare for a Future Together

Pfizer's new business units - which are key to transforming the company - came under Wall Street scrutiny as the company for the first time broke down first quarter sales per unit in an earnings report released April 28


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts